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Abstract
Background: Skin diseases can have high morbidity that can be costly to society and individuals. To date, there has been 
no comprehensive assessment of the burden of skin disease in Canada.
Objectives: To evaluate the burden of 18 skin and subcutaneous diseases from 1990 to 2017 in Canada using the Global 
Burden of Disease (GBD) data.
Methods: The 2017 GBD study measures health loss from 359 diseases and injuries in 195 countries; we evaluated trends 
in population health in Canada from 1990 to 2017 using incidence, prevalence, mortality, years of life lost (YLLs), years lived 
with disability (YLDs), and disability- adjusted life years (DALYs). Data are presented as rates (per 100 000), counts, or per-
cent change with the uncertainty interval in brackets.
Results: From 1990 to 2017 for all skin diseases, DALY rates increased by 8% to 971 per 100 000 (674-1319), YLD rates 
increased by 8% to 897 per 100 000 (616-1235), YLL rates increased by 4% to 74 per 100 000 (53-89), and death rates in-
creased by 18% to 5 per 100 000 (3-6). DALY rates for melanoma increased by 2% to 54 per 100 000 (39-68), for keratino-
cyte carcinoma by 14% to 17 per 100 000 (16-19), and for skin and subcutaneous disease by 8% to 900 per 100 000 
(619-1233). The observed over expected ratios were higher for skin and subcutaneous disease (1.37) and keratinocyte car-
cinoma (1.17) and were lower for melanoma (0.73).
Conclusions: The burden of skin disease has increased in Canada since 1990. These results can be used to guide health 
policy regarding skin disease in Canada.
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Introduction
Accurate and up- to- date data on disease burden at the popu-
lation level are crucial for understanding the important 
causes of death and disability. While mortality from skin dis-
ease is rare, many skin diseases are chronic and associated 
with substantial morbidity.1-4 There are estimates of inci-
dence and prevalence of specific diseases such as psoriasis, 
atopic dermatitis, and melanoma, but to date, there has been 
no comprehensive study of the burden of skin diseases and 
their associated disability in Canada.5-7
The Global Burden of Disease (GBD) study aims to pro-
vide estimates of the fatal and nonfatal burden of disease. 
Metrics such as disability- adjusted life years (DALYs) can 
capture this burden, improving our understanding of skin 
disease and informing future research efforts and public pol-
icy. Skin disease was the 18th leading cause of global disease 
burden according to GBD 2015.8 The 2017 iteration of the 
GBD study measures health loss from death or disability 
resulting from 359 diseases and injuries in 195 countries and 
more than doubles the number of data sources compared 
with GBD 2010.9 GBD data provides a unique opportunity to 
understand the burden of skin disease in Canada. Herein, we 
present GBD 2017 results on morbidity, mortality, incidence, 
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and prevalence for 18 skin and subcutaneous diseases, 
including skin cancers, in Canada from 1990 to 2017. Based 
on an aging and growing population,10 we hypothesized that 
the incidence, prevalence, burden, and mortality of these 
skin diseases will have increased in Canada from 1990 to 
2017.
Materials and Methods
We used GBD 2017 to evaluate Canadian trends in epidemi-
ological patterns from 1990 to 2017. Detailed GBD 2017 
methods have been described previously.9,11,12 Rates and 
numbers of deaths, incident cases and prevalence, years of 
life lost (YLLs) as a result of premature mortality, years lived 
with disability (YLDs), and DALYs are reported here for 
both sexes and all age groups in Canada. Rates are age- 
standardized according to world population estimates by the 
GBD 2017 study.13 The 95% uncertainty intervals (UIs) are 
reported for all estimates except for total skin disease and 
includes all sources of uncertainty such as measurement 
error, systematic biases, and modeling differences from prior 
iterations of GBD. GBD is conducted in accordance with the 
Guidelines for Accurate and Transparent Health Estimates 
Reporting.14,15
Data Sources
The GBD study uses the International Classification of 
Diseases (ICD) to maximize comparability between diseases 
worldwide. For Canada, data are obtained from administra-
tive records, vital registrations, census reports, disease regis-
tries, government and nongovernmental reports, the scientific 
literature, surveys (such as the Canada World Poll 2016), and 
vital statistics. For squamous cell carcinoma, GBD uses the 
cause of death data from vital registrations in Canada and 
calculates squamous cell carcinoma incidence based on the 
mortality incidence ratio. For basal cell carcinoma, GBD 
uses claims and hospital data from Ontario. Information on 
Canadian data sources can be found online at the Global 
Health Data Exchange http:// ghdx. healthdata. org/ geogra-
phy/ canada.
Classification of Skin Disease
Skin diseases were selected by the GBD study and were 
defined by the ninth and 10th revision codes of the ICD,16,17 
resulting in 18 categories of skin and subcutaneous disease 
based on disease prevalence, data adequacy, and standard-
ized disease definitions: (1) acne vulgaris, (2) alopecia 
areata, (3) atopic dermatitis, (4) cellulitis, (5) contact der-
matitis, (6) decubitus ulcer, (7) fungal skin diseases, (8) 
malignant skin melanoma, (9) basal cell carcinoma, (10) 
squamous cell carcinoma, (11) pruritus, (12) psoriasis, 
(13) pyoderma, (14) scabies, (15) seborrheic dermatitis, 
(16) urticaria, (17) viral skin diseases, and (18) other skin 
and subcutaneous diseases, such as pigmentary and atro-
phic skin disorders.
Cause of Death
GBD attributes the cause of death to a single disease that 
initiated the ultimate cause of death, with coding following 
ICD-10 principles. The GBD cause of death hierarchy is 
divided into 4 levels. Level 1 represents all- cause mortal-
ity divided into communicable, maternal, neonatal, and 
nutritional diseases; noncommunicable diseases; and inju-
ries. Level 2 distinguishes these categories into 21 cause 
groups (ie, cardiovascular disease). Level 3 distinguishes 
these causes further by cause (ie, stroke). Finally, Level 4 
represents diseases that may be further disaggregated (ie, 
drug- resistant tuberculosis).11 To assess YLLs and deaths, 
we used data from Levels 3 and 4 of the cause of death 
hierarchy.
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Mortality and YLLs
Age- specific and sex- specific mortality are available for 6 of 
the 18 skin and subcutaneous diseases (cellulitis, decubitus 
ulcer, melanoma, squamous cell carcinoma, other skin and 
subcutaneous diseases, and pyoderma)11 and are modeled 
using the Cause of Death Ensemble model (CODEm).11 
CODEm combines numerous modeling techniques to best 
predict age- specific and sex- specific mortality estimates by 
cause while taking temporal and spatial trends into consider-
ation and using predictive covariates.11 The GBD study cal-
culates YLLs as a measure of cause- specific premature 
mortality. Age- standardized mortality and YLL rates are cal-
culated using the GBD world standard population.11
Years Lived with Disability
Disease modeling meta- regression 2.1 (DisMod- MR 2.1) is 
used to calculate prevalence for each disease taking into 
account data on incidence, prevalence, remission, mortality, 
and disease duration.12,18 The prevalence estimates are mul-
tiplied by disability weights to calculate YLDs resulting 
from a specific cause. Disability weights were derived from 
surveys evaluating the level and progression of disability 
associated with specific causes.12 The prevalence of different 
disease sequelae is used to model comorbidity using a micro-
simulation approach.12
Disability-Adjusted Life Years
DALYs were calculated using the GBD 2017 results for 
YLLs and YLDs, combined.9,11 In GBD, DALYs are used as 
the primary measure to compare disease burden across time 
and between age and sex groups. The GBD world population 
age standard is used to calculate age- standardized rates for 
DALYs, YLLs, and YLDs.9 Rates are calculated and pre-
sented per 100 000 person- years.
Observed Over Expected Ratio
The observed over expected (O/E) ratio is based on a nation’s 
socio- demographic index (SDI) and age- standardized 
DALYs. The expected value of a disease is based solely on 
the SDI, which does not vary over time for a specific region. 
The SDI is a composite average of the rankings of average 
educational attainment, annual income, and fertility rates 
across all areas in the GBD study, expressed on a scale of 
0-1.11 The O/E ratio is therefore a method of comparing 
regions.
Uncertainty Intervals
GBD uses Bayesian estimation methods; every estimate is 
calculated 1000 times to give 95% UIs. The width of the UI 
is reflective of data availability, sample size, and consistency 
of data across multiple sources.9,11 If the calculation of GBD 
estimates requires multiple steps, the uncertainty associated 
with each step is propagated throughout the entire calcula-
tion.19 UIs are calculated for percentage change for each dis-




In Canada, in 2017, skin and subcutaneous diseases had an 
age- standardized incidence rate of 37 898 cases per 100 000 
(95% UI 36 776-39 096) (Table 1) and an age- standardized 
prevalence rate of 28 409 cases per 100 000 (27 917-28 872) 
(Table 2), an increase of 4% and 7%, respectively, from 
1990. Incidence and prevalence rates are subcategorized by 
sex in supplemental Tables S1- S4. Of all skin diseases since 
1990, keratinocyte carcinomas (basal and squamous cell car-
cinomas), had the largest rise in both incidence rate by 748% 
(546%-944%) to 90 per 100 000 (63-124) and prevalence 
rate by 1147% (749%-1751%) to 54 per 100 000 (37-74). 
The incidence and prevalence rates for melanoma have 
increased by 68% (39%-93%) to 15 per 100 000 (11-19) and 
by 81% (53%-108%) to 130 per 100 000 (96-160), respec-
tively. Incidence and prevalence rates were similarly 
increased among males and females from 1990 to 2017, 
though males had a greater relative increase in the preva-
lence (8 per 100 000 [6-12] to 76 per 100 00 [50-113]) and 
incidence (8 per 100 000 [6-11] to 63 per 100 000 [43-98]) of 
squamous cell carcinoma compared with females (5 per 100 
000 [4-7] to 34 per 100 000 [20-56] and 4 per 100 000 [3-6] 
to 28 per 100 000 [17-46], respectively).
Mortality and YLLs
Age- standardized rates and all- age death counts are summa-
rized in Tables 3 and 4 and are subcategorized by sex in sup-
plemental Tables S5- S8. From 1990 to 2017, the death rate 
for all skin diseases in Canada increased by 18% to 5 per 100 
000 (95% UI 3-6). All skin diseases were responsible for 
2281 deaths [1597-2684], an increase of 136% compared 
with 1990, and 42 127 YLLs (30 346-50 573), an increase of 
85%. Melanoma caused the most deaths among skin diseases 
(49% of total deaths from skin disease and 0.4% of all deaths 
in Canada). Melanoma was also the largest contributor to 
YLLs, representing 60% of total YLLs from skin disease, 
and 0.6% of all- cause YLLs. Since 1990, age- standardized 
female and male death rates for melanoma have remained 
stable at 1 per 100 000 (0.9-2) and 2 per 100 000 (1-3), 
respectively. Age- standardized YLL rates for females for all 
skin diseases increased by 6% to 51 per 100 000 (33-71), 
while YLL rates for males remained stable at 99 per 100 000 
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Years Lived with Disability
From 1990 to 2017, age- standardized YLD rates for all 18 
skin and subcutaneous diseases increased by 8% to 897 per 
100 000 (95% UI 616-1235). These are summarized in 
Table 5 and subcategorized by sex in supplemental Tables S9 
and S10. Since 1990, keratinocyte carcinomas had the largest 
increase in YLD rates by 673% (459%-938%) to 2 per 100 
000 (1-4). In 2017, in Canada, skin and subcutaneous dis-
eases, including skin cancer, were responsible for 318 029 
YLDs (222 690-437 915) or 7% of all- cause YLDs. In 2017, 
psoriasis was responsible for the largest number of YLDs (97 
046 [68 760-127 164]) followed by atopic dermatitis (69 065 
[37 470-114 020]), an increase of 68% (61%-76%) and 22% 
(18%-27%), respectively, since 1990. Age- standardized 
YLD trends from 1990 to 2017 were mostly similar across 
skin conditions between males and females, though males 
had a larger increase of 735% (449%-1165%) in YLD rate 
for squamous cell carcinomas (3 per 100 000 [2-6]) 
compared with an increase of 553% (338%-871%) in females 
(2 per 100 000 [1-3]).
Disability-Adjusted Life Years
From 1990 to 2017, age- standardized DALY rates for all skin 
and subcutaneous diseases increased by 8% to 971 per 100 
000 (95% UI 645-1320) and are summarized in Table 6 and 
subcategorized by sex in supplemental Tables S11 and S12. 
Figure 1 presents DALY rates for specific age groups with 
separate estimates for females and males in supplemental 
Figures S1 and S2, respectively. In Canada, all skin diseases 
were responsible for 360 156 all- age DALYs in 2017 (256 
470-485 451), or 4% of all- cause all- age DALYs, an increase 
of 15% since 1990. In 2017, psoriasis was responsible for the 
most all- age DALYs at 97 046 (68 760-127 164). Basal cell 
carcinoma had the greatest percentage increase in total all- 
age DALYs from 1990 to 2017 by 1410% (781%-2191%), 
Table 3. All- Age Death Counts and Age- Standardized Death Rates Per 100 000 for Skin and Subcutaneous Disease in Canada in 1990 
and 2017 and and Cumulative Percentage Changes for 1990-2017 for Both Sexes Combined.
 
All- age deaths (count) (95% UI) Age- standardized death rate (per 100 000) (95% UI)
1990 2017 % Change 1990 2017 % Change
All skin disease 969 (797-1287) 2281 (1597-2684) 136 4 (3-6) 5 (3-6) 18
Melanoma 562 (455-771) 1118 (790-1328) 99 (44-126) 2 (1-2) 2 (1-2) 3 (−24 to 17)
SCC 261 (251-271) 639 (594-690) 145 (125-167) 0.8 (0.8-0.8) 0.9 (0.8-0.9) 10 (1-20)
Skin/subcutaneous disease 146 (91-245) 525 (213-666) 259 (94-385) 0.4 (0.3-0.7) 0.7 (0.3-0.9) 57 (−13 to 110)
  Bacterial skin disease 91 (62-178) 430 (159-556) 374 (108-634) 0.3 (0.2-0.5) 0.6 (0.2-0.8) 110 (−7 to 218)
   Cellulitis 40 (24-79) 218 (70-297) 440 (120-763) 0.1 (0.1-0.2) 0.3 (0.1-0.4) 140 (−1 to 279)
   Pyoderma 50 (32-106) 213 (77-306) 321 (85-579) 0.2 (0.1-0.3) 0.3 (0.1-0.4) 85 (−16 to 192)
  Decubitus ulcer 42 (16-71) 61 (27-123) 44 (7-135) 0.1 (0.1-0.2) 0.1 (0.0-0.2) −40 (−55 to −4)
  Othera 13 (5-20) 33 (10-48) 152 (62-230) 0.04 (0.02-0.1) 0.05 (0.02-0.1) 11 (−22 to 45)
Abbreviations: SCC, squamous cell carcinoma; UI, uncertainity interval.
aOther refers to other skin and subcutaneous disease.
Table 4. All- Age YLL Counts and Age- Standardized YLL Rates Per 100 000 for Skin and Subcutaneous Disease in Canada in 1990 and 
2017 and and Cumulative Percentage Changes for 1990-2017 for Both Sexes Combined.
All- age YLLs (count) (95% UI) Age- standardized YLL rate (per 100 000) (95% UI)
1990 2017 % Change 1990 2017 % Change
All skin disease 22 737 (18 252-29 874) 42 127 (30 346-50 573) 85 71 (57-94) 74 (53-89) 4
Melanoma 15 401 (11 964-20 181) 25 333 (18 284-30 861) 64 (29-83) 48 (37-63) 47 (34-57) −4 (−24 to 6)
SCC 4805 (4607-5009) 9482 (8716-10 310) 97 (81-115) 15 (14-15) 15 (14-16) 0 (−8 to 9)
Skin/subcutaneous disease 2532 (1681-4684) 7312 (3345-9403) 189 (63-292) 8 (5-15) 12 (6-16) 54 (−12 to 107)
  Bacterial skin disease 1692 (1232-3532) 6178 (2627-7888) 265 (72-459) 5 (4-11) 10 (5-14) 93 (−9 to 192)
   Cellulitis 756 (474-1589) 3246 (1159-4344) 329 (84-592) 2 (2-5) 5 (2-7) 125 (−3 to 257)
   Pyoderma 935 (605-2091) 2931 (1198-4280) 213 (54-392) 3 (2-7) 5 (2-8) 67 (−16 to 155)
  Decubitus ulcer 588 (241-999) 671 (317-1315) 14 (−15-78) 3 (0.8-3) 1 (0.6-2) −39 (−54 to −6)
  Othera 252 (112-416) 463 (173-730) 84 (25-135) 0.8 (0.4-1) 0.9 (0.4-1) 5 (−21 to 35)
Abbreviations: SCC, squamous cell carcinoma; UI, uncertainity interval; YLL, years of life lost.
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from 1 (0.4-3) to 17 (6-41). There is a higher overall age- 
standardized burden of melanoma in males (67 per 100 000 
[35-87]) relative to females (43 per 100 000 [31-60]) that has 
remained stable since 1990. The age- standardized DALY 
rate for melanoma remained relatively stable at 54 per 100 
000 (39-68), increased for keratinocyte carcinoma by 14% 
(3%-27%) to 17 per 100 000 (16-19), and increased for skin 
and subcutaneous disease by 8% (6%-11%) to 900 per 100 
000 (619-1233). Age- standardized DALY rates for keratino-
cyte carcinomas increased by 47% (23%-78%) in females to 
6 per 100 000 (5-8) but remained relatively stable in males at 
29 per 100 000 (26-33) and appears to be largely due to a 
46% (23%-77%) increase in squamous cell carcinoma rates 
in females to 6 per 100 000 (5-8) that is not seen in males. 
However, the overall burden of keratinocyte carcinoma is 
still higher in males than in females. Finally, there is a some-
what higher overall burden of nonmalignant skin and subcu-
taneous disease in females (1001 per 100 000 [687-1377]) 
compared with males (801 per 100 000 [552-1098]) with 
increases of 8% (5%-12%) since 1990 in both sexes.
Observed Over Expected
The O/E ratios for 1990 and 2017 are presented in Table 7; sup-
plemental Tables S13 and S14 are based on age- standardized 
DALY rates for each disease. In 2017, Canada had more 
DALYs than expected for keratinocyte carcinoma (O/E: 1.17) 
and overall skin and subcutaneous diseases (O/E: 1.37). For 
melanoma, Canada had a lower burden compared with expected 
(O/E: 0.73). The overall higher burden of skin disease com-
pared with expected is explained in part by chronic 
inflammatory skin diseases including atopic dermatitis (O/E: 
1.33) and psoriasis (O/E: 1.73). Findings were fairly consistent 
for males and females, with the exception that males had a 
lower burden from basal cell carcinoma than expected (O/E: 
0.75) whereas it was higher for females (O/E: 1.38).
Discussion
The present study is the first to comprehensively report on the 
burden of 18 skin diseases in Canada. These results can be used 
to inform resource allocation and health systems responses to 
skin disease in Canada. We report an overall increase in the 
burden of all skin diseases since 1990.20 All- age total DALYs 
for all skin diseases (including skin cancers) account for 4% of 
DALYs in Canada. This places skin diseases 10th among all 
causes of DALYs in Canada, behind neoplasms, cardiovascular 
disease, and diabetes, and ahead of substance use disorders and 
digestive diseases. Skin and subcutaneous diseases, including 
skin cancers, are the eighth leading cause of age- standardized 
DALY rates in Canada, behind substance use disorders and 
ahead of diabetes and kidney diseases and unintentional 
injuries.16
As noted above, the overall burden of skin and subcutane-
ous disease has been steadily increasing since 1990 possibly 
reflecting Canada’s aging population.21 It is also possible that 
this increase is due to secular changes in surveillance, detec-
tion, and statistical recording of skin diseases, particularly skin 
cancer.22-24 Other factors may contribute to individual disease 
burdens such as antimicrobial resistance and sun safety behav-
iors. YLD rates have increased nearly sevenfold for 
Figure 1. Disability- adjusted life year (DALY) rates (per 100 000) for 18 skin diseases in Canada in 2017. BCC, basal cell carcinoma; 
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keratinocyte carcinoma, with smaller increases for skin and 
subcutaneous diseases. The largest relative increase in death 
rate is attributable to bacterial skin diseases such as pyoderma 
and cellulitis possibly due to an immunologically weaker and 
aging population with more comorbidities25 as well as antibi-
otic misuse and resistance.26,27 As populations age, outcomes 
of nonfatal diseases are slowly becoming a larger component 
of the global burden of disease. Decreased mortality rates for 
most of the 359 diseases studied in GBD 2017 have not been 
matched with a similar decline in age- standardized YLD rates, 
likely due to a global aging population.20
While incidence and prevalence rates for all skin diseases 
have modestly increased, rates for keratinocyte carcinomas 
have increased eightfold to 11- fold since 1990 and have 
increased by 68% (39%-93%) and 81% (53%-108%) for mel-
anoma, respectively. The reason for this disproportionately 
large increase in the burden of keratinocyte carcinomas in 
Canada is likely multifactorial. The GBD 2017 cancer study 
found keratinocyte carcinomas to be the leading global cause 
of cancer in 2017, with an increase in incident cases of 33% 
over the past decade—20% of which is attributable to a change 
in the population age structure and 13% to population growth.28 
The much larger increase in incidence and burden in Canada 
may also be due to changes in data sources and increased 
detection and surveillance.22,23 The approximately equal inci-
dence of basal cell carcinoma and squamous cell carcinoma 
seen in our study is compatible with recent estimates from the 
United States.29,30
There was a higher overall burden of skin cancers in 
males and a higher burden of nonmalignant skin and subcu-
taneous disease in females. The sex differences in keratino-
cyte carcinoma burden are likely multifactorial and could be 
related to sun safety behaviors,31 health resource utiliza-
tion,32-34 and tumor stage at presentation.34,35
Some of the trends in our data are comparable to those in 
other populations. Age- standardized malignant melanoma inci-
dence rates in light- skinned individuals in the United States, 
Sweden, Australia, New Zealand, Norway, and the United 
Kingdom have been steadily increasing by 3% each year from 
1982 to 2011 and are projected to increase through 2031.36 
Since 1990, age- standardized melanoma incidence rates have 
increased by 40%-68% in the United States, Canada, and 
Australia.16 Age- standardized keratinocyte carcinoma inci-
dence rates have increased in Canada by 748% (546%-944%) 
and in the United States by 15% (−10% to 59%), while rates 
have decreased in Australia by 20% (−4% to 36%), though the 
incidence rates of all skin cancers in Australia are much higher 
overall16 possibly due to differences in climate and therefore 
time spent outdoors without sun protection. It is unclear why 
keratinocyte carcinoma incidence rates have increased so dra-
matically in Canada compared with other high- income nations, 
as Canadian and Australian populations are aging at similar 
rates.37
Limitations
GBD does not collect subnational data for Canada; provin-
cial, territorial, and regional estimates would be beneficial to 
fully understand the skin and subcutaneous disease burden in 
Canada, as there is variability in disease and risk factor esti-
mates across Canada, and there have been changes in data 
collection methods over time which may impact the 
results.38,39 It would also be beneficial for future iterations of 
the GBD to include different categories of skin disease, such 
as acute vs. chronic urticaria and wounds/ulcers. The 2017 
estimates do not use current vital statistics due to the lag time 
in the release of reported data, and the DALY metric for skin 
diseases does not consider disability from related systems—
for example, mental health comorbidity in atopic dermati-
tis.40-43 Misclassification of disease is possible, particularly 
when relying on administrative coding of diagnoses. Future 
iterations of GBD ought to disaggregate DALYs and YLLs 
attributable to differences in latitude and sunlight exposure.
Conclusion and Future Directions
The disease, including skin cancer, has been steadily increasing 
in Canada since 1990 and is responsible for 4% of DALYs 
nationally. Incidence rates have significantly increased since 
1990, especially for keratinocyte carcinomas and melanoma. 
Subnational estimates of the burden of skin disease in future 
GBD iterations may give more targeted estimates. While our 
study cannot determine the causes of the temporal changes 
observed, Canada’s aging population likely plays a major role. 
This data can be used to inform government policy and advo-
cacy initiatives that aim to reduce the burden of skin disease in 
Canada, particularly targeting sun- protection practices, early 
diagnosis, and public education.
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